News & Events

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

March 14, 2023

IO Biotech to Participate in March 2023 Investor Conferences

February 22, 2023

IO Biotech Announces Appointment of Devin Smith as General Counsel

January 23, 2023

IO Biotech Provides Business Update

January 9, 2023

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

November 9, 2022

IO Biotech Announces Third Quarter Results for 2022

November 9, 2022

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

November 3, 2022

IO Biotech to Participate in the Jefferies London Healthcare Conference

October 31, 2022

IO Biotech Announces Appointment of New Chief Financial Officer

October 13, 2022

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

October 5, 2022

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 6, 2022

IO Biotech Announces Second Quarter Results for 2022

August 11, 2022

IO Biotech to Participate in the 2022 BIO International Convention

June 6, 2022

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

May 26, 2022

IO Biotech to Participate in the Jefferies Healthcare Conference

May 23, 2022

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

May 18, 2022

IO Biotech Announces First Quarter Results for 2022

May 16, 2022

IO Biotech Hosting Key Opinion Leader Webinar Series

April 22, 2022

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

April 12, 2022

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

April 8, 2022

IO Biotech Announces Year-End Results for 2021

March 31, 2022

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

March 8, 2022

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

March 4, 2022

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

March 3, 2022

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

December 9, 2021

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

December 6, 2021

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

November 9, 2021

IO Biotech, Inc. Announces Pricing of Initial Public Offering

November 5, 2021

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

September 14, 2021

IO Biotech Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

July 5, 2021

IO Biotech Strengthens Leadership Team with Appointment of Dr. Muhammad Al-Hajj as Chief Scientific Officer

May 25, 2021

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

January 13, 2021

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma

December 15, 2020

IO Biotech Announces First Patient Dosed in Phase 2 Trial in Head and Neck Cancer Conducted in a Collaboration with Cliniques Universitaires Saint-Luc in Belgium

November 4, 2020

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent

September 18, 2020

Exciting preclinical data confirm T-win MOA: IDO1 vaccine modulates tumor microenvironment leading to tumor reduction

September 15, 2020

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

February 25, 2020

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

May 15, 2019

IO Biotech to Participate in Panel Discussion at 30th Annual Cancer Progress Conference in New York

April 30, 2019

IO Biotech Presents Data on an Immunomodulatory CCL22-based Vaccine at the American Association for Cancer Research Annual Meeting 2019

April 1, 2019

IO Biotech to participate in panel discussion at Biotech Showcase in San Francisco on January 7th

January 5, 2019

New publication: Durable clinical responses in stage III–IV non-small-cell lung cancer patients treated with IDO peptide vaccine in a phase I study

September 28, 2018

IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer

September 27, 2018

New article published: “The T-win® technology: immune-modulating vaccines“

July 9, 2018

IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors

June 6, 2018

Pre-clinical data to be presented at the AACR Annual Meeting 2018

April 13, 2018

New article published: “Immunoregulatory antigens – novel targets for cancer immunotherapy“

March 22, 2018

IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

March 12, 2018

IO Biotech to participate in panel discussion at BIO-Europe Spring in Amsterdam on March 12, 2018

February 20, 2018

New article published in Cancer Research: “The Balance Players of the Adaptive Immune System“

February 20, 2018

IO Biotech presented posters on preclinical studies at SITC Annual Meeting

November 13, 2017

Encouraging five year clinical data for novel next generation Immuno-Oncology therapy In lung cancer presented at ESMO 2017 Congress

October 12, 2017

IO Biotech appoints Dr. Eva Ehrnrooth as Chief Medical Officer

October 12, 2017

SMi conference speech on targeting the tumor microenvironment

June 1, 2017

Poster on planned phase II study at ASCO

May 30, 2017

IO Biotech closes Series A Round including new investor Sunstone Capital to the investor syndicate

December 28, 2016

The immune system strikes back

November 9, 2016

IO Biotech appoints Dr Peter Hirth as Chairman of the Board

October 4, 2016

Positive results from Immunoscore® study presented at ASCO 2016

June 7, 2016

Innovation Fund Denmark grants Industrial PhD Project

May 11, 2016

IO Biotech invited to speak at BioEquity Europe 2016

May 5, 2016

IO Biotech raises 11 Million Euro in a Series A Financing Round

January 5, 2016

IO Biotech CSO speaks at Cancer Biotherapeutics Conference

January 4, 2016

IO Biotech receives InnoBooster grant

November 30, 2015

IO Biotech CEO a panelist at Cancer Progress Conference

April 2, 2014